Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents.

Lennox KA, Behlke MA.

Methods Mol Biol. 2020;2115:23-55. doi: 10.1007/978-1-0716-0290-4_2.

PMID:
32006393
2.

Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology.

Reichenstein I, Eitan C, Diaz-Garcia S, Haim G, Magen I, Siany A, Hoye ML, Rivkin N, Olender T, Toth B, Ravid R, Mandelbaum AD, Yanowski E, Liang J, Rymer JK, Levy R, Beck G, Ainbinder E, Farhan SMK, Lennox KA, Bode NM, Behlke MA, Möller T, Saxena S, Moreno CAM, Costaguta G, van Eijk KR, Phatnani H, Al-Chalabi A, Başak AN, van den Berg LH, Hardiman O, Landers JE, Mora JS, Morrison KE, Shaw PJ, Veldink JH, Pfaff SL, Yizhar O, Gross C, Brown RH Jr, Ravits JM, Harms MB, Miller TM, Hornstein E.

Sci Transl Med. 2019 Dec 18;11(523). pii: eaav5264. doi: 10.1126/scitranslmed.aav5264.

3.

Single-Stranded Nucleic Acids Regulate TLR3/4/7 Activation through Interference with Clathrin-Mediated Endocytosis.

Järver P, Dondalska A, Poux C, Sandberg A, Bergenstråhle J, Sköld AE, Dereuddre-Bosquet N, Martinon F, Pålsson S, Zaghloul E, Brodin D, Sander B, Lennox KA, Behlke MA, El-Andaloussi S, Lehtiö J, Lundeberg J, LeGrand R, Spetz AL.

Sci Rep. 2018 Oct 26;8(1):15841. doi: 10.1038/s41598-018-33960-4.

4.

Non-nucleotide Modification of Anti-miRNA Oligonucleotides.

Lennox KA, Vakulskas CA, Behlke MA.

Methods Mol Biol. 2017;1517:51-69.

PMID:
27924473
5.

An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway.

Robertson KA, Hsieh WY, Forster T, Blanc M, Lu H, Crick PJ, Yutuc E, Watterson S, Martin K, Griffiths SJ, Enright AJ, Yamamoto M, Pradeepa MM, Lennox KA, Behlke MA, Talbot S, Haas J, Dölken L, Griffiths WJ, Wang Y, Angulo A, Ghazal P.

PLoS Biol. 2016 Mar 3;14(3):e1002364. doi: 10.1371/journal.pbio.1002364. eCollection 2016 Mar.

6.

Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.

Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD.

Mol Oncol. 2016 May;10(5):693-703. doi: 10.1016/j.molonc.2015.12.010. Epub 2015 Dec 22.

7.

Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.

Lennox KA, Behlke MA.

Nucleic Acids Res. 2016 Jan 29;44(2):863-77. doi: 10.1093/nar/gkv1206. Epub 2015 Nov 17.

8.

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish.

Pauli A, Montague TG, Lennox KA, Behlke MA, Schier AF.

PLoS One. 2015 Oct 5;10(10):e0139504. doi: 10.1371/journal.pone.0139504. eCollection 2015.

9.

Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors.

Sarvestani ST, Stunden HJ, Behlke MA, Forster SC, McCoy CE, Tate MD, Ferrand J, Lennox KA, Latz E, Williams BR, Gantier MP.

Nucleic Acids Res. 2015 Jan;43(2):1177-88. doi: 10.1093/nar/gku1343. Epub 2014 Dec 24.

10.

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.

Hammond SM, McClorey G, Nordin JZ, Godfrey C, Stenler S, Lennox KA, Smith CI, Jacobi AM, Varela MA, Lee Y, Behlke MA, Wood MJ, Andaloussi SE.

Mol Ther Nucleic Acids. 2014 Nov 25;3:e212. doi: 10.1038/mtna.2014.63.

11.

Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.

Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA.

Mol Ther Nucleic Acids. 2013 Aug 27;2:e117. doi: 10.1038/mtna.2013.46.

12.

U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.

Goraczniak R, Wall BA, Behlke MA, Lennox KA, Ho ES, Zaphiros NH, Jakubowski C, Patel NR, Zhao S, Magaway C, Subbie SA, Jenny Yu L, Lacava S, Reuhl KR, Chen S, Gunderson SI.

Mol Ther Nucleic Acids. 2013 May 14;2:e92. doi: 10.1038/mtna.2013.24. Erratum in: Mol Ther Nucleic Acids. 2013 Jul 30;2:e111.

13.

Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs.

Ramachandran S, Karp PH, Osterhaus SR, Jiang P, Wohlford-Lenane C, Lennox KA, Jacobi AM, Praekh K, Rose SD, Behlke MA, Xing Y, Welsh MJ, McCray PB Jr.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):544-51. doi: 10.1165/rcmb.2012-0430OC.

14.

RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Keiser MS, Geoghegan JC, Boudreau RL, Lennox KA, Davidson BL.

Neurobiol Dis. 2013 Aug;56:6-13. doi: 10.1016/j.nbd.2013.04.003. Epub 2013 Apr 10.

15.

In vivo SELEX for Identification of Brain-penetrating Aptamers.

Cheng C, Chen YH, Lennox KA, Behlke MA, Davidson BL.

Mol Ther Nucleic Acids. 2013 Jan 8;2:e67. doi: 10.1038/mtna.2012.59.

16.

A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator.

Ramachandran S, Karp PH, Jiang P, Ostedgaard LS, Walz AE, Fisher JT, Keshavjee S, Lennox KA, Jacobi AM, Rose SD, Behlke MA, Welsh MJ, Xing Y, McCray PB Jr.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13362-7. doi: 10.1073/pnas.1210906109. Epub 2012 Aug 1.

17.

Pancreas-enriched miRNA refines endocrine cell differentiation.

Kredo-Russo S, Mandelbaum AD, Ness A, Alon I, Lennox KA, Behlke MA, Hornstein E.

Development. 2012 Aug;139(16):3021-31. doi: 10.1242/dev.080127. Epub 2012 Jul 4.

18.

Modulating Anti-MicroRNA-21 Activity and Specificity Using Oligonucleotide Derivatives and Length Optimization.

Muñoz-Alarcón A, Guterstam P, Romero C, Behlke MA, Lennox KA, Wengel J, El Andaloussi S, Langel U.

ISRN Pharm. 2012;2012:407154. doi: 10.5402/2012/407154. Epub 2012 Feb 7.

19.

Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.

Kim N, Jiang D, Jacobi AM, Lennox KA, Rose SD, Behlke MA, Salem AK.

Int J Pharm. 2012 May 1;427(1):123-33. doi: 10.1016/j.ijpharm.2011.08.014. Epub 2011 Aug 12.

20.

Chemical modification and design of anti-miRNA oligonucleotides.

Lennox KA, Behlke MA.

Gene Ther. 2011 Dec;18(12):1111-20. doi: 10.1038/gt.2011.100. Epub 2011 Jul 14. Review.

PMID:
21753793
21.

miRNAs control insulin content in pancreatic β-cells via downregulation of transcriptional repressors.

Melkman-Zehavi T, Oren R, Kredo-Russo S, Shapira T, Mandelbaum AD, Rivkin N, Nir T, Lennox KA, Behlke MA, Dor Y, Hornstein E.

EMBO J. 2011 Mar 2;30(5):835-45. doi: 10.1038/emboj.2010.361. Epub 2011 Feb 1.

22.

A direct comparison of anti-microRNA oligonucleotide potency.

Lennox KA, Behlke MA.

Pharm Res. 2010 Sep;27(9):1788-99. doi: 10.1007/s11095-010-0156-0. Epub 2010 Apr 28.

PMID:
20424893
23.

Structure and activity of putative intronic miRNA promoters.

Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL.

RNA. 2010 Mar;16(3):495-505. doi: 10.1261/rna.1731910. Epub 2010 Jan 14.

24.

Central delivery of Dicer-substrate siRNA: a direct application for pain research.

Doré-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, Rose SD, Beaudet N, Behlke MA, Sarret P.

Mol Ther. 2008 Jul;16(7):1331-9. doi: 10.1038/mt.2008.98. Epub 2008 Jun 3.

25.

Characterization of modified antisense oligonucleotides in Xenopus laevis embryos.

Lennox KA, Sabel JL, Johnson MJ, Moreira BG, Fletcher CA, Rose SD, Behlke MA, Laikhter AL, Walder JA, Dagle JM.

Oligonucleotides. 2006 Spring;16(1):26-42.

PMID:
16584293

Supplemental Content

Loading ...
Support Center